Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada

Clin Mol Hepatol. 2024;30(2):281-283. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0214

View: 612 Download: 9

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 812 Download: 42 Crossref: 1

Review

Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases

Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Jia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu

Clin Mol Hepatol. 2024;30(1):16-36. Published online October 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0315

View: 2916 Download: 246 Crossref: 1

Letter to the Editor

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han

Clin Mol Hepatol. 2023;29(3):810-811. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0129

View: 1691 Download: 56 Web of Science: 1

Editorial

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 2314 Download: 53 Web of Science: 2 Crossref: 2

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 3288 Download: 92 Web of Science: 2 Crossref: 2

Review

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0239

View: 7745 Download: 352 Web of Science: 26 Crossref: 29

1

Nonalcoholic fatty Liver disease as a risk factor of cardiovascular disease

Moon Young Kim , Soon Koo Baik

Clin Mol Hepatol. 2008;14(1):1-3. Published online March 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.1.1

View: 4719 Download: 63 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Received March 1, 2024 Accepted March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157 [Accepted]

View: 495 Download: 58

1 |

Viewed By 5122	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4960	MAFLD: How is it different from NAFLD?
Viewed By 4869	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3570	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3539	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 67	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search